Publications by authors named "L Condreay"
Background: Combination treatments, targeting multiple disease processes, benefit subjects with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, predicting treatment response and exacerbation risk remain challenging.
Objective: To identify genetic associations with AECOPD risk and response to combination therapy (fluticasone furoate, umeclidinium bromide and vilanterol).
Article Synopsis
- Treatment with mepolizumab, in addition to glucocorticoids, for eosinophilic granulomatosis with polyangiitis (EGPA) leads to longer remission times, reduced glucocorticoid usage, and fewer relapses.
- A study was conducted to see if genetic factors could predict how well patients respond to this treatment by analyzing genetic variants in 61 EGPA subjects from the MIRRA trial.
- The research found no significant genetic variants linked to treatment response, indicating that identifying genetic markers for responders and non-responders may not be possible based on the current data.
Purpose: No studies have investigated genetic effects on quality of life (QoL) measurements like improvements in the St George's Respiratory Questionnaire (SGRQ) scores for chronic obstructive pulmonary disease treatments with fluticasone propionate/salmeterol (FSC). Therefore, in addition to testing genetic effects on change from baseline in trough forced expiratory volume in 1 s (FEV), genetic associations that may predict SGRQ response to FSC treatment were investigated in this analysis.
Methods: This post hoc exploratory genome-wide genetic analysis included subjects from 10 clinical trials: NCT01772134, NCT01772147, NCT00633217, NCT01817764, NCT01879410, NCT01822899, NCT01323621, NCT01342913, NCT01323634, and NCT01706328.
Introduction: Improved understanding of genetic effects on response to treatments with novel approaches for COPD with peripheral blood eosinophilia, such as mepolizumab (a humanized monoclonal antibody to IL-5), may improve treatment outcomes. We conducted a study to identify genetic variants associated with efficacy of mepolizumab COPD.
Materials And Methods: Using generalized linear and logistic regression models, genome-wide association analyses were performed to investigate genetic associations with frequency of moderate and/or severe COPD exacerbations in COPD subjects receiving mepolizumab (weeks 0-52).